PLSE (Pulse Biosciences, Inc Common Stock (DE))
Insider Trading Activity
Every open-market purchase and sale reported by PLSE officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-02 | Liane Rae Teplitsky | Chief Operating Officer | Buy | — | — |
| 2026-08-28 | Jon Skinner | Chief Financial Officer | A | — | — |
| 2026-08-28 | Liane Rae Teplitsky | Chief Operating Officer | Buy | — | — |
| 2026-08-28 | Liane Rae Teplitsky | Chief Operating Officer | A | — | — |
| 2026-06-15 | Manmeet Singh Soni | Director | A | — | — |
| 2026-06-15 | Mahkam Zanganeh | Director | A | — | — |
| 2026-06-15 | ROBERT W DUGGAN | Director | A | — | — |
| 2026-06-15 | Maria Sainz | Director | A | — | — |
| 2026-06-15 | Broek Richard van den | Director | A | — | — |
| 2026-05-15 | ROBERT W DUGGAN | Director | Buy | — | — |
| 2026-05-11 | PAUL A LAVIOLETTE | Chief Executive Officer | Buy | — | — |
| 2026-05-11 | ROBERT W DUGGAN | Director | Buy | — | — |
| 2026-05-11 | PAUL A LAVIOLETTE | Chief Executive Officer | Buy | — | — |
| 2026-04-03 | DARRIN UECKER | Chief Technology Officer | A | — | — |
| 2026-02-23 | Kevin Patrick Danahy | Chief Commercial Officer | MIXED | — | — |
| 2026-02-17 | Kevin Patrick Danahy | Chief Commercial Officer | MIXED | — | — |
| 2026-02-11 | Kevin Patrick Danahy | Chief Commercial Officer | MIXED | — | — |
| 2026-02-06 | Maria Sainz | Director | A | — | — |
| 2025-10-07 | Kevin Patrick Danahy | Chief Commercial Officer | MIXED | — | — |
| 2025-09-22 | Kevin Patrick Danahy | Chief Commercial Officer | MIXED | — | — |
| 2025-09-18 | DARRIN UECKER | Chief Technology Officer | MIXED | — | — |
| 2025-09-15 | DARRIN UECKER | Chief Technology Officer | MIXED | — | — |
| 2025-09-12 | ROBERT W DUGGAN | Director | Buy | — | — |
| 2025-08-19 | Broek Richard van den | Director | A | — | — |
| 2025-08-19 | Manmeet Singh Soni | Director | A | — | — |
| 2025-08-19 | ROBERT W DUGGAN | Director | A | — | — |
| 2025-08-19 | Mahkam Zanganeh | Director | A | — | — |
| 2025-07-16 | Steven Weber | Principal Accounting Officer | A | — | — |
| 2025-06-16 | DARRIN UECKER | Chief Technology Officer | Sell | — | — |
| 2025-02-11 | Mahkam Zanganeh | Director | X | — | — |
| 2025-01-13 | PAUL A LAVIOLETTE | Chief Executive Officer | A | — | — |
| 2024-12-20 | Burke Thomas Barrett | — | Sell | — | — |
| 2024-12-18 | ROBERT W DUGGAN | Director | X | — | — |
| 2024-12-17 | ROBERT W DUGGAN | Director | Buy | — | — |
| 2024-12-17 | ROBERT W DUGGAN | Director | Buy | — | — |
| 2024-12-13 | ROBERT W DUGGAN | Director | Buy | — | — |
| 2024-09-30 | Mitchell E. Levinson | Chief Strategy Officer | X | — | — |
| 2024-08-13 | Mahkam Zanganeh | Director | A | — | — |
| 2024-08-13 | PAUL A LAVIOLETTE | Director | A | — | — |
| 2024-08-13 | Manmeet Singh Soni | Director | A | — | — |
| 2024-07-22 | Burke Thomas Barrett | President and CEO | X | — | — |
| 2024-07-09 | Kevin Patrick Danahy | Chief Commercial Officer | X | — | — |
| 2024-07-09 | Mahkam Zanganeh | Director | X | — | — |
| 2024-07-09 | ROBERT W DUGGAN | Director | X | — | — |
| 2024-07-08 | Burke Thomas Barrett | President and CEO | X | — | — |
| 2024-07-08 | Mitchell E. Levinson | Chief Strategy Officer | X | — | — |
| 2024-06-24 | Mahkam Zanganeh | Director | A | — | — |
| 2024-06-24 | Broek Richard van den | Director | A | — | — |
| 2024-06-24 | Burke Thomas Barrett | President and CEO | A | — | — |
| 2024-06-24 | Manmeet Singh Soni | Director | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Director | 48,820,236 | — |
| — | Director | 802,348 | — |
| — | Chief Technology Officer | 284,406 | — |
| — | Chief Strategy Officer | 102,301 | — |
| — | President and CEO | 63,172 | — |
| — | Chief Commercial Officer | 48,298 | — |
| — | EVP & GM, Dermatology | 39,300 | — |
| — | Chief Executive Officer | 15,000 | — |
| — | Chief Operating Officer | 3,094 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the PLSE quote page; the site-wide leaderboard is on the insider transactions hub.